Injury-Induced Type I IFN Signaling Regulates Inflammatory Responses in the Central Nervous System

Reza Khoroooshi and Trevor Owens

*J Immunol* published online 18 June 2010
http://www.jimmunol.org/content/early/2010/06/18/jimmunol.0901753

---

**Subscription**  Information about subscribing to *The Journal of Immunology* is online at:  [http://jimmunol.org/subscription](http://jimmunol.org/subscription)

**Permissions**  Submit copyright permission requests at:  [http://www.aai.org/About/Publications/JI/copyright.html](http://www.aai.org/About/Publications/JI/copyright.html)

**Email Alerts**  Receive free email-alerts when new articles cite this article. Sign up at:  [http://jimmunol.org/alerts](http://jimmunol.org/alerts)
Injury-Induced Type I IFN Signaling Regulates Inflammatory Responses in the Central Nervous System

Reza Khoroooshi and Trevor Owens

Injury to the CNS induces an innate glial response, in which microglia and astrocytes become activated. This response is essential for the induction of cytokines and chemokines, which initiate a variety of cellular responses including the migration of peripheral immune cells into the damaged tissue. The activation of glial cells and the entry of leukocytes may be beneficial for repair and regeneration processes in the damaged CNS but may also exacerbate neurodegeneration (1, 2).

The initial glial response involves TLR signaling, which can induce proinflammatory cytokines (3, 4), among them type I IFNs. Type I IFNs (IFN-α and IFN-β) play a critical role in the innate immune response against viral infection (5). The signaling pathway for both IFN-α and IFN-β involves a common surface receptor, IFNAR. IFNAR is associated with STAT1 and STAT2, which together with IFN regulatory factor (IRF)9 form a complex that binds to IFN-stimulated response element in promotor regions and stimulates type I IFN-dependent gene transcription including IFR7 (6, 7). IFR7 has been described as a master regulator of type I IFN signaling (8, 9).

Type I IFN signaling is normally associated with antiviral immune responses (10). IFN-β is also used in the treatment of multiple sclerosis, and mice with defective type I IFN signaling develop more severe autoimmune encephalomyelitis (EAE) (11, 12), indicating the involvement of type I IFN signaling in the regulation of CNS inflammation. Involvement of type I IFN in a noninfectious injury-induced glial response has not been studied.

A well-established and widely used model to study the glial response after brain injury is an entorhinal axonal lesion. The transection of projections from entorhinal cortex to the hippocampus leads to anterograde axonal degeneration and loss of synapses in the outer molecular layer of the dentate gyrus, followed by glial activation, leukocyte infiltration, and sprouting (13–20). Involvement of TLR signaling as well as cytokines (TNF-α and IL-1β) and chemokines (CCL2 and CXCL10) in glial response and recruitment of leukocytes in the lesion-reactive hippocampus have been described previously (15, 17, 21, 22). We previously described glial upregulation of STAT1 and STAT2 (21), which suggested the involvement of type I IFN signaling.

The aim of this study was to examine the involvement and functional significance of type I IFN signaling in lesion-induced glial responses. We show that sterile axonal lesion induces IFR7 and IRF9 gene expression and that this is IFNAR dependent. Immunohistochemical staining and flow cytometry localized IFR7 to Mac1/CD11b+ macrophages/microglia in lesion-reactive hippocampus at 1 d postlesion. Leukocyte infiltration was increased in IFNAR-deficient mice. Unlike wild-type (WT) mice, axonal lesion did not induce an increase in CXCL10, but it induced an increase in matrix metalloproteinase (MMP)9 gene expression in IFNAR-knockout (KO) mice. These findings identify a role for type I IFN in regulating innate responses to CNS injury.

Materials and Methods

Animals

Adult female mice deficient in STAT1 (STAT1-KO) 129x6/SvEv background (23) were purchased from Taconic Farms (Germantown, NY). IFNAR-KO on 129x6/SvEv background were purchased from B&K Universal Limited (Hull, U.K.). IRF7-KO on C57BL/6 background were purchased from Riken BRC (Tsukuba, Japan) with agreement from Dr. T. Taniguchi (Department of Immunology, University of Tokyo, Tokyo, Japan) (9), and IFNAR-KO on C57BL/6 background (11) were provided by Dr. M. Prinz (Department of Neuropathology, University of Freiburg, Germany). WT mice (C57BL/6 and 129x6/SvEv) were purchased from Taconic (Taconic Europe, Ry, Denmark). These experiments were conducted according to the guidelines of the National Danish Animal Research Committee.

Entorhinal cortex lesioning and tissue preparation

Under anesthesia, adult female (18–20 g) mice were placed in a Kopf stereotactic apparatus (Kopf Instruments, Tutunga, CA). The entorhino-
dentate perforant path projection was transected as described previously (21).

For immunohistochemical analysis, mice were perfused transcardially with PBS, followed by 4% paraformaldehyde (Sigma-Aldrich, Broendby, Denmark) in PBS. The brains were removed and postfixed in PBS containing 4% paraformaldehyde for 2 h on ice, then immersed in 30% sucrose in PBS overnight at 4 °C, frozen with CO₂-snow, and stored at −20 °C until sectioning. For flow cytometry and quantitative real-time RT-PCR analysis, mice were perfused transcardially with PBS, and brains were removed aseptically.

Single- and dual-labeling immunohistochemistry

Immunohistochemical staining was performed as described previously (21). In brief, after blocking endogenous peroxidases, the sections were incubated overnight with rabbit anti-IRF7 Ab (SC-9083; Santa Cruz Biotechnology, Santa Cruz, CA), rat anti-mouse Mc-1/CD11b (MCA7172; Serotec, Oxford, U.K.) (to identify microglia/macrophages), or rabbit anti-GFAP (Z0334; Dianova) (to identify astrocytes), and in the following day, the sections were incubated with secondary biotinylated Ab (Amersham Biosciences, Little Chalfont, U.K.). The sections were finally incubated with streptavidin-HRP (PO397; DakoCytomation) and detected using diaminobenzidine (Sigma-Aldrich).

For dual-labeling immunofluorescence, sections were incubated with rabbit anti-IRF7 and with rat anti-monoclonal Mc-1/CD11b or monoclonal mouse anti-IRF9 (E12, Sigma-Aldrich), followed by incubation with fluorescent secondary Abs, Alexa 488-labeled goat anti-rabbit (A11034; Invitrogen, Taastrup, Denmark) and Alexa 568-labeled goat anti-rat (A11077; Invitrogen), as described previously (21). Images were acquired using either an Olympus BX51 microscope (Olympus, Ballerup, Denmark) connected to an Olympus DP71 digital camera and a Confocal laser scanning fluorescence microscope (Olympus FV1000; Olympus, Hamburg, Germany). Images were combined using Adobe Photoshop CS version 8.0 to visualize double-labeled cells. To verify Ab specificity, control sections displayed no staining comparable with that seen with primary Abs (data not shown).

Western blotting

Western blot analysis was performed as described previously (21). Both contralateral and ipsilateral hippocampi were isolated from PBS-perfused mice and lysed in lysis buffer. Cell lysate was mixed with sample buffer, denatured by boiling, and separated by electrophoresis in an 8–10% polyacrylamide gel. The separated proteins were transferred to a nitrocellulose membrane (Bio-Rad, Hercules, CA). The membranes were blocked for 1 h at room temperature in 5% nonfat dry milk in PBS containing 0.1% Tween 20 (PBST). The membranes were then incubated with rabbit anti-IRF7 and/or rabbit anti-IRF9 and/or mouse anti-IRF3 monoclonal Abs (C-terminal, Sigma-Aldrich), followed by incubation with fluorescent secondary Abs, Alexa 488-labeled goat anti-rabbit (A11034; Invitrogen, Taastrup, Denmark) and Alexa 568-labeled goat anti-rat (A11077; Invitrogen), as described previously (21). Images were acquired using either an Olympus BX51 microscope (Olympus, Ballerup, Denmark) connected to an Olympus DP71 digital camera and a Confocal laser scanning fluorescence microscope (Olympus FV1000; Olympus, Hamburg, Germany). Images were combined using Adobe Photoshop CS version 8.0 to visualize double-labeled cells. To verify Ab specificity, control sections displayed no staining comparable with that seen with primary Abs (data not shown).

Flow cytometry

To measure leucocyte entry in response to axonal injury, hippocampi were homogenized and incubated with blocking solution to block nonspecific staining as described previously (21). Cells were then stained with rat anti-mouse CD45-conjugated PE, rat anti-CD11b–conjugated PerCP, and hamster anti-mouse TCRβ–conjugated APC Abs (BD Biosciences, Erembodegem, Belgium) to detect microglia/macrophages or T cells, respectively (15, 17). Data were collected on a FACSCalibur (BD Biosciences, San Jose, CA) and analyzed using FlowJo software (Tree Star, Ashland, OR) (21).

To sort microglia and macrophages, hippocampi were pooled from six mice, and a similar experiment was performed as described above with few modifications. Homogenates were enriched for mononuclear cells by centrifugation through 33% isotonic Percoll prior to blocking the nonspecific staining. After staining with respective Abs, cells were sorted by a FACS-Vantage/Diva Sorting Flow Cytometer (BD Biosciences). Total RNA was extracted using Trizol reagent as previously described (21) and converted to cDNA, and quantitative real-time PCR was performed as described above. ΔCT values for IRF7 gene expression were then calculated. ΔCT is the difference in CT between IRF7 gene and the internal reference control gene, 18S rRNA.

Data analysis

Results were analyzed by two-tailed paired/unpaired t test or one-way ANOVA with Bonferroni’s posttest using GraphPad Prism software (GraphPad Software, San Diego, CA). A value of p < 0.05 was considered to be statistically significant. Data are presented as mean ± SEM.

Results

Lesion-induced IRF7 gene expression was STAT1 and IFNAR dependent

IRF7 mRNA was constitutively expressed at low levels in unmanipulated hippocampi from WT, IFNAR-KO, and STAT1-KO mice (data not shown). Levels of IRF7 increased significantly in lesion-reactive hippocampi of WT mice at 1, 3, and 5 d (Fig. 1A). In contrast, axonal lesion did not induce a significant increase in IRF7 gene expression in IFNAR-KO and STAT1-KO mice (Fig. 1B). Whether or not mice were on 129sv/SvEv (Fig. 1A) or C57Bl/6 (Fig. 1B) background had no effect on these events.

Like IRF7, IRF9 mRNA was constitutively expressed at low levels in unmanipulated hippocampi from both WT and IFNAR-KO mice (data not shown). IRF9 mRNA levels increased in the lesion-reactive hippocampus at 1 d postlesion, and this was also IFNAR dependent (Fig. 1C).

In addition to IRF7 and IRF9, we also examined IRF3 gene expression. IRF3 is involved in the early induction of type I IFNs in antiviral immune response (25). IRF3 was constitutively expressed in unmanipulated hippocampi in both WT and IFNAR-KO mice. Unlike IRF7 and IRF9, there was no induction of IRF3 at 1 d after lesion (data not shown). IRF7 was expressed by microglia/macrophages in the outer molecular layer of dentate gyrus

We next examined IRF7 distribution and cellular localization in the denervated outer molecular layer of the dentate gyrus at 1 d post lesion. IRF7 immunoreactivity was not evident in unmanipulated...
FIGURE 1. Injury-induced increase in IRF7 and IRF9 gene expression was IFNAR and STAT1 dependent. A, IRF7 mRNA increased significantly in lesion-reactive hippocampi of 129s6/SvEv WT but not in IFNAR-KO and STAT1-KO mice at 1, 3, and 5 d postaxonal lesion. B, IRF7 mRNA increased significantly in lesion-reactive hippocampi of C57BL/6 WT but not in IFNAR-KO mice on C57BL/6 background. C, IRF9 gene expression was increased in lesion-reactive hippocampi of WT but not in IFNAR-KO mice at 1 d postlesion. Groups of matched contralateral and lesion-reactive hippocampi were analyzed by two-tailed paired Student t test. *Statistically significant differences versus contralateral as follows: A, 1 day postlesion (dpl), p = 0.009; 3 dpl, p = 0.031; 5 dpl, p = 0.031; B, WT, p = 0.0039; and C, WT, p = 0.001. Error bars represent SEM. C, contralateral; L, lesion-reactive hippocampi.

FIGURE 2. IRF7 immunoreactivity increased in lesion-reactive hippocampi at 1 d postlesion. A, IRF7 immunoreactivity was not evident in contralateral hippocampus. B, Axonal lesion-induced increase IRF7 immunoreactivity was detected in a few cells (arrow) dispersed within denervated outer molecular layer. C, Higher magnification of IRF7 immunoreactive cells (arrow) in B. D–K, Double labeling of IRF7 with Mac-1/CD11b and GFAP showed that IRF7 colocalized with Mac-1/CD11b (Fig. 2D–G) and not with GFAP (Fig. 2H–K), indicating expression in microglia/macrophages. IRF7 protein was also detected by Western blotting (data not shown). We identified relevant bands on the basis of their absence of CD45dimCd11b+ microglia were in CD45high cells (Fig. 3). Because of the limited number of CD45high CD11b+ macrophages sorted by flow cytometry from hippocampi, we were not able to detect IRF7 gene expression in macrophages (Fig. 3).

Lesion-induced leukocyte infiltration was increased in IFNAR-KO mice

The upregulation of downstream components of type I IFN signaling indicates involvement in axonal lesion-induced glial response. Low levels of type I IFN gene expression could be detected in hippocampal samples by quantitative real-time PCR (data not shown). However, expression was difficult to detect, and it was not possible to reliably determine whether axonal-lesion influenced type I IFN induction, consistent with findings by Ousman et al. (10), in which the levels of type I IFN within the CNS were at the limit of detection even after several days postvirus infection.

To examine the functional significance of type I signaling in this model, leukocyte recruitment to the lesion-reactive hippocampi was analyzed by flow cytometry, measuring the proportion of CD45high cells (Fig. 4A). Proportions of blood-derived leukocytes were similarly low in unmanipulated hippocampi from WT and IFNAR-KO mice, regardless of strain background. The proportion of CD45high cells was significantly increased in lesion-reactive hippocampi of both WT and IFNAR-KO mice compared with the contralateral hippocampus of each mouse, regardless of whether WT and IFNAR-KO mice were on C57BL/6 (data not shown) or 129s6/SvEv (Fig. 4B) backgrounds. However, the proportions of...
infiltrating CD45 high cells were significantly higher in IFNAR-KO than in WT mice (Fig. 4B) at 1 d. Lesion-induced increase in leukocyte infiltration in IFNAR-KO mice compared with WT was transient and was not seen at 3 and 5 d postlesion (Fig. 4B), although the proportion of infiltrating CD45 high cells were increased by lesion in both WT and IFNAR-KO mice at these time points (Fig. 4B). The fold increase in leukocyte infiltration in lesion-reactive versus contralateral hippocampus at 1 d in IFNAR-KO mice was 3-fold higher than WT (Fig. 4C).

Leukocyte infiltration to lesion-reactive hippocampus includes both T cells and macrophages (15, 17). To ask whether IFNAR deficiency differentially affected T cell and macrophage infiltration, we counted proportions of CD11b+ and TCR-ß(CD45 high) cells. Whereas the proportion of macrophages (CD45 highCD11b+) doubled in lesioned IFNAR-deficient hippocampus compared with WT, the lesion-induced increase in T cells (CD45 highTCR-ß) was not affected by IFNAR deficiency (data not shown). There was no significant difference between the proportions of CD45 dimCD11b+ microglia in lesion-reactive hippocampi of WT and IFNAR-KO mice (data not shown).

Lesion-induced CXCL10 and MMP9 gene expression were IFNAR regulated

Our findings indicate that IFNAR deficiency leads to increased leukocyte infiltration in lesion-reactive hippocampus. The involvement of cytokines (including TNF-ß and IL-1ß) and chemokines (including CCL2 and CXCL10) in leukocyte entry to CNS has been shown previously (21, 26, 27). Interestingly, type I IFN signaling regulates MMP9 expression (29). We next examined whether increased infiltration correlated with changes in expression of lesion-induced CCL2, CXCL10, TNF-ß, IL-1ß, and MMP9. As previously shown (17, 21), axonal injury induced upregulation of CXCL10 (Fig. 5A), CCL2 (Fig. 5B), TNF-ß (Fig. 5C), and IL-1ß (Fig. 5D) in WT mice. In IFNAR-KO mice, axonal injury also induced a significant increase in CCL2 (Fig. 5B), TNF-ß (Fig. 5C), and IL-1ß (Fig. 5D) but not in CXCL10 gene expression (Fig. 5A). Unlike WT mice, MMP9 gene expression increased significantly in lesion-reactive hippocampi from IFNAR-KO mice (Fig. 5E).

FJ and glial staining in response to axonal lesion

To examine whether lack of type I IFN signaling may influence axonal degeneration and glial response in the outer molecular layer of dentate gyrus, we performed FJ, Mac-1/CD11b, and GFAP staining on brain sections from WT and IFNAR-KO mice at 1, 3, and 5 d.

Discussion

Our findings show the involvement of type I IFN signaling in response to sterile injury in the CNS. Type I IFN signaling in the CNS is normally associated with antiviral immune responses (10, 30).
lates itively regulates the induction of type I IFN, which in turn regu-
sponses as well. To injury, which suggest their involvement in noninfectious re-
study, we showed CNS upregulation of IRF7 and IRF9 in response 
for initiation of type I IFN response to infection. In the current 
constitutive expression of IRF7 and IRF9 may therefore be necessary 
antiviral defense. The CNS is susceptible to infection, and con-
Most importantly, these two reports emphasize the essential role 
ences in size and behavior compared with WT littermates (9, 32).
and we have shown a role for type I IFN in regulating leukocyte infiltration 
in lesion-reactive hippocampi of WT and IFNAR-KO mice at 1 d post-
axonal lesion. (E) In contrast to WT, lesion induced a significant increase in 
MMP9 gene expression in IFNAR-deficient mice at 1 d post axonal lesion. Data were analyzed using one-way ANOVA with Bonferroni’s posthoc analysis. Error bars represent SEM. Statistically significant differences versus contralateral. *p < 0.05; **p < 0.01; ***p < 0.001. †Not significantly different between contralaterals for each message. C, contralateral; L, lesion-reactive hippocampi.

Type I IFNs exert a wide range of effects on inflammatory processes in 
the CNS during infection and in EAE, in both of which pathogen-
associated signals may play a role. The functional significance of 
type I IFN in sterile injury-induced response in the CNS is therefore 
of interest. Similar to findings in viral infection models (10, 30), the 
expression of IRF7 and IRF9 gene increased following axonal le-
son, and this increase was IFNAR dependent (10). Other studies 
have shown a role for type I IFN in regulating leukocyte infiltration 
to the CNS in EAE models (11, 12, 31), and we have shown a 
similar effect in response to sterile injury. Our results support 
an innate signaling role for type I IFN in the CNS.

IRF7 and IRF9 belong to a family of transcription factors with 
diverse functions including host defense, regulation of cell growth, 
apoptosis, and immune cell development. However, mice deficient in 
IRF7 and IRF9 develop normally and have no obvious differences in size and behavior compared with WT littermates (9, 32).
Most importantly, these two reports emphasize the essential role of 
IRF7 and IRF9 in the regulation of type I IFN signaling and antiviral defense. The CNS is susceptible to infection, and consitu-
tive expression of IRF7 and IRF9 may therefore be necessary for 
imitation of type I IFN response to infection. In the current 
study, we showed CNS upregulation of IRF7 and IRF9 in response to 
injury, which suggest their involvement in noninfectious responses as well.

IRF7 gene expression is specifically of interest, because it pos-
tively regulates the induction of type I IFN, which in turn regu-
lates IRF7 induction. The cellular expression of IRF7 may there-
fore be indicative of the source of type I IFN. We have been able to 
show induction of IFN-α and IFN-β by RT-PCR in lesion-
reactive hippocampus, but this has been difficult to reproduce, and we have been unable to localize the cellular source of IFN 
I. This is probably due to a combination of low expression level 
and that current methods are not sensitive enough to detect the 
differences in type I IFN induced by injury in this model. Identifi-
cation and localization of type I IFN in the CNS is of interest, 
particularly in response to viral infection. To our knowledge, only 
two studies have identified the source of type I IFN in the CNS. 
Delhaye et al. (30) identified that neurons produced IFN-α in 
response to infection, and Teige et al. (12) found that during 
EAE, both infiltrating cells and cells with the morphology of 
microglia expressed IFN-β. Otherwise, surrogate markers of 
downstream signaling associated with type I IFN signaling have 
been used to identify type I IFN-producing cells within the CNS 
(10, 30).

Our results pointed to upregulation of IRF7 in Mac-1/CD11b+
microglia/macrophages, although absence of IRF7 immunoreac-
tivity in other cell types does not exclude their ability to produce 
type I IFN. IRF7 protein expression could be detected in 
unmanipulated hippocampal samples as well as in contralateral 
and lesion-reactive hippocampi. Furthermore, both PCR and Western blot analysis showed that the level of IRF7 protein expression was higher in WT mice compared with IFNAR-KO mice, although not significantly. The immunostaining of sections with IRF7 Ab showed increased but dispersed IRF7+ cells in the outer molecular layer of dentate gyrus in response to axonal lesion. This increased 
immunoreactivity was not detected by Western blotting, which 
probably reflects lower sensitivity of Western blotting of whole 
hippocampal isolates versus immunohistochemistry, by which 
IRF7 expression could be detected even in very few cells.

We showed that the axonal lesion resulted in increased ex-
pression of IRF7 gene, and this increase was IFNAR dependent. 
IFNAR-dependent induction of IRF7 has also been shown in

FIGURE 5. Lesion-induced CXCL10 and MMP9 gene expression was 
IFNAR dependent. Whereas CXCL10 gene expression (A) did not increase 
significantly in lesion-reactive hippocampi of IFNAR-deficient mice, 
CCL2 (B), TNF-α (C), and IL-1β (D) were significantly increased in 
lesion-reactive hippocampi of both WT and IFNAR-KO mice at 1 d post-
axonal lesion. (E) In contrast to WT, lesion induced a significant increase in 
MMP9 gene expression in IFNAR-deficient mice at 1 d post axonal lesion. Data were analyzed using one-way ANOVA with Bonferroni’s 
FIGURE 6. FJ, GFAP, and Mac-1/CD11b staining in the outer molecular 
layer of dentate gyrus in response to axonal lesion. A and B. Images showing 
FJ staining in lesion-reactive hippocampi of WT versus IFNAR-KO at 1 d. FJ 
staining was present at very low level in the outer molecular layer of dentate 
gyrus at 1 d postaxonal lesion. Levels of FJ staining increased in the outer 
molecular layer of dentate gyrus at 3 d after axonal lesion of both WT (inset in 
A) and IFNAR-KO (inset in B). No differences in FJ staining were observed 
between IFNAR-KO and WT mice. Axonal lesion caused an increase GFAP 
(C, D, arrows) and Mac-1/CD11b immunoreactivity (E, F, arrows) in the outer 
molecular layer of dentate gyrus. However, there were no differences in 
GFAP and Mac-1/CD11b immunoreactivity between IFNAR-KO and WT 
D, Mac-1/CD11b. DG, dentate gyrus; OML, outer molecular layer. Original magnification 
×10 (A, B, insets), ×40 (C–F). Scale bars, 20 μm.
of type I IFN signaling, expression in astrocytes and microglia and reduces leukocyte infiltration (44). It has been shown that type I IFN inhibits expression of leukocytes (28, 43). In the CNS, both astrocytes and microglia can respond to type I IFN (30, 34–36). Type I IFN is capable of stimulating interferon regulatory factor (IRF)-7 and IRF-9 gene expression in the central nervous system (J. Virol. 70: 7514–7527).

Unlike in WT mice, CXCL10 gene expression was not elevated in lesioned IFNAR-KO mice. In contrast, CCL2, TNF-α, and IL-1β were similarly upregulated in both IFNAR-KO and WT mice. This contrasts with findings in EAE, in which elevated macrophage infiltration correlated with increased levels of TNF-α, CCL2, and CXCL10 expression in IFNAR- and IFN-β-KO compared with WT mice (11, 12). As shown by others and ourselves in entorhinal cortex lesion and other models of brain injury, glial cells represent a major source for many of these mediators. Previous studies identified microglia and astrocytes as a prominent source of CCL2 (17). IL-1β and TNF are also glial derived (37, 38), and we must assume that the leukocyte contribution was not significant in this case. The differences in effect on CXCL10 may reflect involvement of adjuvant in the EAE model or other differences between these systems. It has been demonstrated that an IFN-stimulated response element is contained in the CXCL10 promoter (39, 40). Type I IFN is capable of stimulating CXCL10 production by hepatocytes in vitro, and ischemia/reperfusion-triggered intrahepatic CXCL10 expression was diminished in IFNAR-KO mice (41). The induction of CXCL10 has been used as biomarker to measure type I IFN activity (42). Our study suggests that type I IFN signaling normally either allows or directly stimulates CXCL10 production in the CNS in response to axonal injury. Our findings further suggest that type I IFN signaling may regulate leukocyte entry through this or other mechanisms involving disruption of blood-brain barrier (29). MMP9 is involved in degradation of extracellular matrix and facilitating the recruitment of leukocytes (28, 43). In the CNS, both astrocytes and microglia express MMP9 (28), and it is also expressed by infiltrating macrophages (44). It has been shown that type I IFN inhibits MMP9 expression in astrocytes and microglia and reduces leukocyte infiltration to the CNS (29, 43, 45–47). We find that in the absence of type I IFN signaling, MMP9 was significantly increased. This could both result from and contribute to the increased leukocyte entry into the hippocampus of IFNAR-deficient mice in response to axonal lesion.

These findings of innate expression and response to type I IFN in the CNS likely have relevance to understanding the effectiveness of IFN-β as a therapeutic for multiple sclerosis. Innate signaling pathways in the CNS offer potential new targets for therapy for neuroinflammatory diseases.

Acknowledgments
We thank Dina Draeby, Mie Rytz Hansen, and Pia Nyborg Nielsen for excellent technical support. We also thank Dr. Alicia Babcock for providing RNA samples used in preliminary studies. We thank Per Svenningsen for help with the confocal laser microscopy and Inger Andersen for help with cell sorting.

Disclosures
The authors have no financial conflicts of interest.

References


